|Dr. Seth Lederman M.D.||Co-Founder, Chairman, Chief Exec. Officer, Pres||472.5k||N/A||59|
|Dr. Donald W. Landry M.D., Ph.D.||Co-Founder and Director||45.75k||N/A||62|
|Mr. Bradley Saenger CPA||Chief Financial Officer and Treasurer||301.36k||N/A||43|
|Dr. Gregory M. Sullivan M.D.||Chief Medical Officer and Sec.||335k||N/A||51|
|Mrs. Jessica Edgar Morris||Exec. VP of Operations||N/A||N/A||N/A|
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The companys product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.